PRNewsWire
23 Jun 2026, 10:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of observing a statistically significant reduction in Stage III-IV cancers. — The failure of a primary clinical endpoint for a core product significantly damages the company's valuation and commercial viability.
-0.90A securities fraud class action lawsuit has been filed against GRAIL and its executives, alleging they misled investors regarding the NHS-Galleri trial design and results. — Legal liabilities and allegations of fraud create long-term financial risk and damage investor confidence in management.
-0.50GRAIL stock plummeted approximately 50% following the disclosure that the trial did not meet its primary endpoint. — This confirms a massive loss of market capitalization and high volatility for the asset.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities fraud class action lawsuit following a 50% stock price drop after failing to meet a primary clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
